Glaucoma drainage stent and preparation method thereof

By using a glaucoma drainage stent made of biodegradable pure iron or iron-based alloy materials, the problems of lumen blockage and displacement in the existing technology have been solved, achieving long-term stable drainage effect and biocompatibility, and reducing complications caused by foreign body stimulation.

CN118986637APending Publication Date: 2024-11-22MICROPORT VISIONPOWER MEDTECH (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310573960.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing minimally invasive glaucoma drainage implants have problems such as lumen blockage, drainage device displacement, and filtration channel scarring, which lead to device failure and the risk of secondary implantation.

Method used

Glaucoma drainage stents are prepared using biodegradable pure iron or biodegradable iron-based alloy materials. The stent body includes a first end, a middle support, and a second end connected in sequence, and multiple valve plates are set inside. The surface is coated with an anticoagulant coating, and in some embodiments, a protective film is also included. The stents are prepared by processes such as laser cutting, machining, or additive manufacturing.

Benefits of technology

It provides long-term longitudinal support, reduces the risk of stent dislocation and blockage, avoids scarring and scarring, maintains the stability of the drainage channel, reduces complications caused by foreign body irritation, and has good biocompatibility and antibacterial properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986637A_ABST
    Figure CN118986637A_ABST
Patent Text Reader

Abstract

The invention relates to a glaucoma drainage stent and a preparation method thereof. The glaucoma drainage stent comprises a tubular stent body, the stent body comprises a first end, a middle supporting part and a second end which are sequentially connected, and the stent body is made of first degradable pure iron or first degradable iron-based alloy. The stent body of the glaucoma drainage stent is made of the degradable pure iron and the degradable iron-based alloy, compared with other degradable materials, sufficient mechanical strength can be provided in the earlier stage, the risk of stent dislocation caused by insufficient material strength is reduced, meanwhile, the risk of stent pipeline blockage is reduced, and it is expected that after a filter channel is formed, the drainage effect is good. The glaucoma drainage support is gradually degraded in eyes, a permanent drainage channel is provided, and the problems of scars, scar wrapping and the like caused by foreign matter stimulation are effectively solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical devices, and in particular to a glaucoma drainage stent and a preparation method thereof. Background Art

[0002] Glaucoma is a chronic, progressive and irreversible ophthalmic disease. It is a progressive optic neuropathy caused by damage to retinal ganglion cells, which leads to typical structural and functional defects of the eyeball. If glaucoma patients fail to receive timely treatment, they will suffer from severe vision loss and even blindness in the later stages. So far, the treatment of glaucoma mainly focuses on controlling the increase in intraocular pressure, including drug therapy and surgical treatment. The main drugs for the treatment of glaucoma are α-receptor agonists, prostaglandin analogs, β-adrenergic receptor blockers and carbonic anhydrase inhibitors. However, as the popularity of glaucoma drugs continues to rise, the systemic adverse reactions caused by their topical use have attracted people's attention. In addition, problems such as hormone dependence and drug resistance caused by drug use remain to be solved. Glaucoma surgery is mainly divided into two categories according to the mechanism of reducing intraocular pressure: increasing the drainage of aqueous humor and reducing the production of aqueous humor. According to the different drainage routes, the increase of aqueous humor drainage can be divided into two subtypes: external drainage and internal drainage, including Schlemm's canal drainage, suprachoroidal drainage and subconjunctival drainage. The reduction of aqueous humor production can be divided into three subtypes: cyclophotocoagulation, sonoprosthesis and cyclocryotherapy.

[0003] Traditional glaucoma filtration surgery is complicated, accompanied by extremely high risks and costs. Complications such as shallow anterior chamber and lumen displacement may occur in the later stage of implantation. In order to minimize damage to eyeball tissue, minimally invasive drainage implantation has been continuously developed, opening up a new direction for glaucoma treatment. However, current minimally invasive drainage implants for glaucoma (MIGS) products still have problems such as lumen blockage, drainage device displacement, and filtration tract scarring, which lead to the risk of device failure and secondary implantation. Summary of the invention

[0004] Based on this, it is necessary to provide a glaucoma drainage stent and a preparation method thereof to reduce the problems existing in traditional technologies such as drainage stent lumen obstruction, drainage stent displacement, and filtration bleb scarring.

[0005] A glaucoma drainage stent comprises a tubular stent body, wherein the stent body comprises a first end, an intermediate support portion and a second end connected in sequence, and the material of the stent body comprises a first degradable pure iron or a first degradable iron-based alloy.

[0006] In some embodiments, a plurality of valve sheets with holes are disposed inside the support body, and the plurality of valve sheets are arranged at intervals along the extension direction of the tube, and the material of the valve sheets includes a second degradable pure iron or a second degradable iron-based alloy.

[0007] In some embodiments, the first degradable iron-based alloy and the second degradable iron-based alloy comprise iron-platinum alloy, and the mass percentage of platinum in the first degradable iron-based alloy and the second degradable iron-based alloy is independently 1% to 5%; or,

[0008] The first degradable iron-based alloy and the second degradable iron-based alloy include an iron-copper alloy or an iron-silver alloy. In the first degradable iron-based alloy and the second degradable iron-based alloy, the mass percentage of copper or silver is independently 1% to 15%.

[0009] In some embodiments, the stent body satisfies at least one of the following conditions:

[0010] 1) The glaucoma drainage stent can be implanted in Schlemm's canal to drain the aqueous humor of the anterior chamber;

[0011] 2) The first end and / or the second end is a tapered structure;

[0012] 3) The outer diameter of the intermediate support portion is larger than the inner diameter of Schlemm's canal.

[0013] In some of the embodiments, it further includes: an anti-coagulation coating disposed on the surface of the stent body.

[0014] In some embodiments, the anticoagulant coating satisfies any one or more of the following conditions:

[0015] 1) The drug loading of the anticoagulant coating is 0.1 mg / cm 2 ~3mg / cm 2 ;

[0016] 2) The drug of the anticoagulant coating includes any one or more of aspirin, dipyridamole, clopidogrel, warfarin and heparin drugs;

[0017] 3) The anticoagulant coating is connected to the stent body by covalent bonds.

[0018] In some embodiments, a protective film is further provided on the surface of the stent body between the stent body and the anticoagulant coating;

[0019] Optionally, the material of the protective film includes iron nitride or iron fluoride.

[0020] In some embodiments, the material of the protective film includes iron nitride, and the thickness of the protective film is 1 μm to 12 μm; or,

[0021] The material of the protective film includes iron fluoride, and the thickness of the protective film is 100 μm to 300 μm.

[0022] A method for preparing a glaucoma drainage stent comprises the following steps:

[0023] A tubular stent body is prepared using a first degradable pure iron or a first degradable iron-based alloy as a material. The stent body comprises a first end, a middle support portion and a second end which are connected in sequence, thereby obtaining a glaucoma drainage stent.

[0024] In some embodiments, the processing method of the stent body includes at least one of tube laser cutting, machining, additive manufacturing and powder metallurgy forming process; and / or,

[0025] It also includes: forming a plurality of valve sheets with holes inside the bracket body, the plurality of valve sheets are arranged at intervals along the extension direction of the tube, and the material of the valve sheets includes a second degradable pure iron or a second degradable iron-based alloy.

[0026] In some of the embodiments, it also includes: forming an anti-coagulation coating on the surface of the stent body.

[0027] In some embodiments, the step of forming an anticoagulant coating on the surface of the stent body includes:

[0028] Performing surface treatment on the stent body to introduce reactive groups on the surface of the stent body;

[0029] A solution containing anticoagulant drugs is applied to the treated surface of the stent body, so that the reactive groups contained in the stent body react with the anticoagulant drugs to form the anticoagulant coating on the surface of the stent body.

[0030] In some of the embodiments, before the step of forming an anticoagulant coating on the surface of the stent body, the method further includes: performing a nitriding treatment or a fluoriding treatment on the stent body.

[0031] In some embodiments, the nitridation step includes: -3 Pa~3×10 -3 Pa, the temperature of the bracket body is less than 50°C, nitrogen is introduced into the chamber at a pressure of 0.2Pa to 3.5Pa, a glow discharge plasma is formed at 5MHz to 20MHz, and then a pulse bias voltage of -1kV to -10kV is applied for 3h to 7h to form a protective film with a thickness of 1μm to 12μm;

[0032] The fluorination treatment step includes: placing the stent body in a hydrofluoric acid aqueous solution with a mass percentage concentration of 40% to 50%, stirring and soaking for 12 hours to 96 hours, and forming a protective film with a thickness of 100 μm to 300 μm on the surface of the stent body.

[0033] The above-mentioned glaucoma drainage stent includes a tubular stent body, which can be implanted in Schlemm's canal. After implantation, due to the pressure difference from the anterior chamber, the aqueous humor enters the Schlemm's canal along the stent body and enters the aqueous humor circulation system, thereby reducing the patient's intraocular pressure and alleviating glaucoma symptoms. The stent body material is made of degradable pure iron or degradable iron-based alloy. The degradation products of iron have no obvious toxicity to human tissues. The degradation products can be cleared by macrophages in the body. Excessive iron ions will be transported through body fluids and quickly excreted from the body through the sweat and desquamation of shed mucosal cells, skin cells, and hair. Compared with other degradable materials, it can provide sufficient mechanical strength in the early stage, reduce the risk of stent dislocation due to insufficient material strength, and reduce the risk of stent pipeline blockage. After the formation of the filtration channel, the glaucoma drainage stent gradually degrades in the eye, providing a permanent drainage channel, effectively reducing the scars and scar wrapping caused by foreign body stimulation. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 A schematic diagram of the structure of the support body in some embodiments of the present invention;

[0035] Figure 2 for Figure 1 A schematic diagram of the cavity of the stent body shown;

[0036] Figure 3 This is a comparison chart of the mechanical stability test of the glaucoma drainage stent prepared in Example 1 and Comparative Example 1. DETAILED DESCRIPTION

[0037] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively below in conjunction with the specific embodiments. Preferred embodiments of the present invention are provided in the specific embodiments. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0039] Unless otherwise specified or there is a contradiction, the terms or phrases used in this invention have the following meanings:

[0040] In the present invention, "first", "second", and "third" are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first", "second", and "third" may explicitly or implicitly include at least one of the features.

[0041] In the description of the present invention, “plurality” means at least two, for example, two, three, etc., unless otherwise clearly and specifically defined.

[0042] In the present invention, "one or several" refers to any one, any two or any two or more of the listed items. Among them, "several" refers to any two or any two or more.

[0043] In the present invention, the percentage concentration involved, unless otherwise specified, refers to the final concentration. The final concentration refers to the proportion of the added component in the system after the addition of the component.

[0044] The words "preferably", "more preferably", etc. in the present invention refer to embodiments of the present invention that may provide certain beneficial effects in certain circumstances. However, other embodiments may also be preferred under the same circumstances or other circumstances. In addition, the description of one or more preferred embodiments does not imply that other embodiments are not applicable, nor is it intended to exclude other embodiments from the scope of the present invention.

[0045] When a numerical range is disclosed in the present invention, the above range is considered to be continuous and includes the minimum and maximum values ​​of the range, as well as every value between such minimum and maximum values. Further, when a range refers to an integer, every integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise indicated, all ranges disclosed in the present invention should be understood to include any and all subranges included therein.

[0046] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0047] The terms "including" and "having" and any variations thereof in the embodiments of the present invention are intended to cover non-exclusive inclusions. For example, a process, method, system, product, or device that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units that are not listed, or may optionally include other steps or components that are inherent to these processes, methods, products, or devices.

[0048] Reference to "embodiments" in the present invention means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described in the present invention may be combined with other embodiments.

[0049] There are currently three main types of minimally invasive drainage implants (MIGS) for glaucoma, including the XEN glaucoma drainage implant, the CyPass implant, and the iStent micro-drainage implant. The XEN glaucoma drainage implant is a hydrophilic tube formed by cross-linking porcine gelatin and glutaraldehyde. It can be implanted either internally or externally to drain the aqueous humor into the subconjunctival space. The material used in the XEN has good biocompatibility and induces less inflammatory response, which helps to reduce postoperative scarring. However, its structure is a straight tube with poor structural fixation, and it is prone to displacement after long-term implantation. The CyPass implant is implanted into the suprachoroidal space through a clear corneal incision. Three retaining rings are provided at the proximal end of the implant to prevent implant displacement. Compared with the preoperative intraocular pressure without medication, the average intraocular pressure was reduced by 7.4 mmHg, and 85% of patients no longer took glaucoma medications; however, in the subsequent five-year follow-up, postoperative complications such as drainage lumen obstruction and corneal endothelial cell loss occurred. The iStent micro-drainage stent is made of non-magnetic titanium with a heparin coating. It is implanted in the trabecular meshwork area to allow the aqueous humor to flow directly from the anterior chamber into the Schlemm's canal, thereby accelerating the flow of aqueous humor. Compared with traditional glaucoma drainage methods, the iStent does not have complications such as scarring of the filtration bleb, but there are still problems such as postoperative hemolysis, stent blockage, and postoperative inflammatory response.

[0050] Based on this, the first aspect of the present invention provides a glaucoma drainage stent, including a tubular stent body, the stent body including a first end, an intermediate support part and a second end connected in sequence, and the material of the stent body includes a first degradable pure iron or a first degradable iron-based alloy.

[0051] The material used for the stent body is degradable pure iron or degradable iron-based alloy. Fe is an essential element for the human body and has many important roles and functions in the human body. The standard corrosion potential of iron is -0.44V, which is significantly higher than that of pure Zn and pure Mg. It has a stronger degradation cycle and mechanical strength stability. In a physiological environment, the degradation of iron is carried out through electrochemical reactions, as shown below:

[0052] Fe→Fe 2+ +2e - (Anode reaction)

[0053] O2+2H2O+4e- →4OH - (cathode reaction).

[0054] In body fluids, Fe 2+ Will be with OH - Further combined to form ferrous hydroxide: Fe 2+ +2OH - →Fe(OH)2↓. Due to the presence of oxygen in physiological fluids, part of the ferrous hydroxide is converted into ferric hydroxide by the following reaction: 4Fe(OH)2+O2→2H2O+4Fe(OH)3↓.

[0055] The degradation products of Fe have no obvious toxicity to human tissues. The degradation products can be cleared by macrophages in the body. Excessive Fe ions will be transported through body fluids and quickly excreted from the body through the sweat and desquamation of shed mucosal cells, skin cells, and hair. According to the applicant's research and analysis, compared with other degradable metal materials, iron and iron-based alloys have a longer degradation cycle, can provide long-term longitudinal support performance, avoid the risk of insufficient material strength and stent dislocation, and match the formation of filtration channels; compared with degradable polymer materials, iron and iron-based alloys have better mechanical strength and reduce the risk of stent pipeline blockage. Compared with non-degradable materials, after the filtration channel is formed, the degradable pure iron or iron-based alloy gradually degrades in the eye, providing a permanent drainage channel, and can also avoid scars caused by foreign body stimulation, drainage stent scar wrapping and other problems.

[0056] In some embodiments, the material of the stent body includes first degradable pure iron, and the mass percentage of iron element is ≥ 99.9%.

[0057] In some other embodiments, the material of the stent body includes a first degradable iron-based alloy. Specifically, the first degradable iron-based alloy includes a degradable iron-based memory alloy or a degradable iron-based antibacterial alloy.

[0058] In one embodiment, the first degradable iron-based alloy comprises an iron-platinum alloy, in which the mass percentage of platinum is 1% to 5% and the rest is iron. f The above temperatures are in the high-temperature austenite phase. When stress is applied, deformation causes a phase transition from austenite to martensite. When the applied stress is eliminated, the material immediately rebounds and the crystal structure returns to the austenite phase. The transformation temperature of the first degradable iron-based alloy can be regulated by adjusting the heat treatment temperature and time. By adjusting, the transformation temperature can be lower than the ambient temperature such as human body temperature. After the glaucoma drainage stent is implanted in Schlemm's canal, the structure at the time of shaping can be maintained for a long time, and permanent plastic deformation due to squeezing of the trabecular meshwork, Schlemm's canal and surrounding tissues is not likely to occur.

[0059] In another embodiment, the first degradable iron-based alloy includes an iron-copper alloy or an iron-silver alloy, and in the first degradable iron-based alloy, the mass percentage of copper or silver is 1% to 15%, and the rest is iron. Copper or silver is added to pure iron, and the stent has antibacterial properties through the release of silver ions or copper ions, which reduces the irritation of the stent to the human body, avoids the risk of postoperative inflammation after implantation of the drainage stent, and improves the therapeutic effect of the medical device. In addition, the introduction of copper or silver causes the second phase particles to appear inside the iron-based alloy, and the strength of the alloy can be significantly increased by precipitation strengthening.

[0060] In some embodiments, the glaucoma drainage stent can be implanted in Schlemm's canal to drain the aqueous humor of the anterior chamber. Specifically, the first end and / or the second end of the stent body is a tapered structure. The end of the stent body is set to a tapered structure to facilitate puncturing into the Schlemm's canal during implantation surgery.

[0061] Furthermore, in some embodiments, the outer diameter of the middle support portion is greater than the inner diameter of the Schlemm's canal. The stent body can open the Schlemm's canal, expand the natural diameter of the Schlemm's canal, and increase the drainage effect.

[0062] In some of the embodiments, the stent body can be shaped by bending, and the bending rate thereof is greater than the bending rate of Schlemm's canal.

[0063] In some embodiments, a plurality of valve sheets with holes are provided inside the stent body, and the plurality of valve sheets are arranged at intervals along the extension direction of the tube, and the material of the valve sheets includes a second degradable pure iron or a second degradable iron-based alloy. The plurality of valve sheets are provided inside the stent body, which can further ensure that the patient will not have the risk of shallow anterior chamber complications due to too rapid reduction of intraocular pressure in the early stage of implantation, and the intermediate support part will gradually degrade in the later stage, the longitudinal support force of the stent will be insufficient, and the stent will collapse, and the internal valve sheets will gradually degrade, thereby improving the patency of aqueous humor drainage and maintaining the stability of aqueous humor drainage in the early and late stages of the drainage stent. After the permanent drainage pathway is formed, the stent body and the valve sheets can be completely degraded.

[0064] Specifically, in the second degradable pure iron, the mass percentage of iron element is ≥ 99.9%. It can be understood that the iron element content in the second degradable pure iron can be the same as or different from the iron element content in the first degradable pure iron.

[0065] Specifically, the second degradable iron-based alloy includes an iron-platinum alloy, in which the mass percentage of platinum is 1% to 5%, and the rest is iron. Alternatively, the second degradable iron-based alloy includes an iron-copper alloy or an iron-silver alloy, in which the mass percentage of copper or silver is 1% to 15%, and the rest is iron. It is understood that the second degradable iron-based alloy may be the same as the first degradable iron-based alloy or may be different.

[0066] See also Figure 1 , a schematic diagram of the structure of the bracket body. Figure 1 In the embodiment, the stent body includes a first end 11, an intermediate support portion 13 and a second end 12 which are connected in sequence. Among them, the second end 12 is a conical structure, which is convenient for puncturing into the Schlemm's canal during the implantation operation. The intermediate support portion 13 can provide good support and bending performance to support the Schlemm's canal. During the implantation process, one end of the stent body together with the anterior chamber, the intermediate support portion 13 and the other end are retained in the Schlemm's canal. After implantation, due to the pressure difference from the anterior chamber, the aqueous humor enters the Schlemm's canal along the stent body and enters the aqueous humor circulation system, thereby reducing the patient's intraocular pressure and alleviating glaucoma symptoms.

[0067] Please also read Figure 2 , a plurality of valve sheets 21 with holes are provided inside the stent body, and the plurality of valve sheets 21 are arranged at intervals along the extension direction of the tube, and the material of the valve sheets 21 includes a second degradable pure iron or a second degradable iron-based alloy. Specifically, the thickness, number and through-hole diameter of the valve sheets 21 can be customized according to the actual intraocular pressure of the patient. In addition, the degradation speed of each valve sheet 21 can be the same or different, and a customized design can also be performed. At the same time, each valve sheet 21 can also select a combination of different thicknesses, numbers and through-hole diameters to form a better drainage effect.

[0068] In some embodiments, the glaucoma drainage stent further comprises an anticoagulant coating disposed on the surface of the stent body. Specifically, the drug in the anticoagulant coating comprises any one or more of aspirin, dipyridamole, clopidogrel, warfarin and heparin drugs.

[0069] Specifically, the anticoagulant coating is connected to the stent body by covalent bonds, which can improve the stability of the anticoagulant coating and make the anticoagulant coating play a better role.

[0070] In some embodiments, the drug loading of the anticoagulant coating is 0.1 mg / cm 2 ~3mg / cm 2 Optionally, the drug loading of the anticoagulant coating may be, but is not limited to, 0.1 mg / cm 2 , 0.2mg / cm 2 , 0.4mg / cm 2 , 0.6mg / cm 2 , 0.8mg / cm 2 , 1mg / cm 2 , 1.2mg / cm 2 , 1.4mg / cm 2 、1.6mg / cm 2 、1.8mg / cm 2, 2mg / cm 2 , 2.2mg / cm 2 , 2.4mg / cm 2 , 2.6mg / cm 2 , 2.8mg / cm 2 、3mg / cm 2 Or a range consisting of any two of these values.

[0071] Setting an anticoagulant coating on the surface of the glaucoma drainage stent can cooperate with the stent body to reduce the risks of blockage of the drainage duct and scarring caused by intraoperative hemolysis and foreign body stimulation, and inhibit the growth of scar tissue.

[0072] Furthermore, a protective film is provided on the surface of the stent body between the stent body and the anticoagulant coating. The material of the protective film includes iron nitride or iron fluoride. The above-mentioned film layer is formed on the surface of the stent body, which can reduce the degradation rate of the degradable pure iron or degradable iron-based alloy, and avoid the risk of rapid loss of mechanical strength in the early stage after implantation due to excessive degradation rate.

[0073] In some embodiments, the material of the protective film includes iron nitride, and the thickness of the protective film is 1 μm to 12 μm. Optionally, the thickness of the protective film can be, but is not limited to, 1 μm, 2 μm, 4 μm, 5 μm, 6 μm, 8 μm, 10 μm, 12 μm, or a range consisting of any two of these values. Specifically, the protective film can be a film formed after the stent body reacts with nitrogen.

[0074] In some embodiments, the material of the protective film includes iron fluoride, and the thickness of the protective film is 100 μm to 300 μm. Optionally, the protective thickness can be but not limited to 100 μm, 120 μm, 140 μm, 160 μm, 180 μm, 200 μm, 220 μm, 240 μm, 260 μm, 280 μm, 300 μm or a range consisting of any two of these values. Specifically, the protective film can be a film formed after the stent body reacts with the fluorine element.

[0075] The above-mentioned glaucoma drainage stent has at least the following advantages:

[0076] (1) The above-mentioned glaucoma drainage stent includes a tubular stent body, which can be implanted in Schlemm's canal. After implantation, due to the pressure difference from the anterior chamber, the aqueous humor enters the Schlemm's canal along the stent body and enters the aqueous humor circulation system, thereby reducing the patient's intraocular pressure and alleviating glaucoma symptoms. The stent body material is made of degradable pure iron or degradable iron-based alloy. The degradation products of iron have no obvious toxicity to human tissues. The degradation products can be cleared by macrophages in the body. Excessive iron ions will be transported through body fluids and quickly excreted from the body through the sweat and desquamation of shed mucosal cells, skin cells, and hair. Compared with other degradable materials, it can provide sufficient mechanical strength in the early stage to avoid the risk of insufficient material strength and stent dislocation, while reducing the risk of stent pipeline blockage. After the expected filtration channel is formed, the glaucoma drainage stent gradually degrades in the eye, providing a permanent drainage channel, effectively reducing the problems of scars and scar wrapping caused by foreign body stimulation. The above-mentioned stent body also has good biocompatibility and can obtain antibacterial properties or superelastic properties.

[0077] (2) The above-mentioned glaucoma drainage stent is provided with multiple valves inside to avoid the risk of shallow anterior chamber in the early stage of implantation. In the later stage, the stent body gradually degrades to avoid the risk of insufficient longitudinal support force of the stent body and insufficient flow of aqueous humor in the cavity, thereby maintaining the stability of aqueous humor discharge before the permanent drainage channel is formed.

[0078] (3) The surface of the above-mentioned glaucoma drainage stent is provided with an anticoagulant coating, which cooperates with the stent body to inhibit the growth of scar tissue and avoid the risk of hemolysis blocking the drainage channel, resulting in device failure and secondary implantation.

[0079] The second aspect of the present invention provides a method for preparing a glaucoma drainage stent, comprising the following steps:

[0080] A tubular stent body is prepared using a first degradable pure iron or a first degradable iron-based alloy as a material. The stent body comprises a first end, a middle support portion and a second end which are connected in sequence, thereby obtaining a glaucoma drainage stent.

[0081] In some embodiments, the processing technology of the stent body includes at least one of tube laser cutting, machining, additive manufacturing and powder metallurgy forming processes.

[0082] Furthermore, it also includes: forming a plurality of valve sheets with holes inside the stent body, the plurality of valve sheets are arranged at intervals along the extension direction of the tube, and the material of the valve sheets includes a second degradable pure iron or a second degradable iron-based alloy. Arranging a plurality of valve sheets inside the stent body can ensure that in the early stage of implantation, the patient will not have the risk of shallow anterior chamber complications due to too rapid reduction of intraocular pressure. In the later stage, the middle support part of the stent gradually degrades, the longitudinal support force of the stent is insufficient, and the stent collapses. At the same time, the internal valve sheet gradually degrades, improves the patency of aqueous humor drainage, maintains the stability of aqueous humor drainage before and after the drainage stent, and after the permanent drainage pathway is formed, the stent body and the valve sheet can be completely degraded. It can be understood that the valve sheet can be integrally formed with the stent body, and the valve sheet can also be formed after the stent body is formed. In a specific example, the valve sheet is formed by argon arc welding.

[0083] In some embodiments, the preparation method of the glaucoma drainage stent further comprises: forming an anticoagulant coating on the surface of the stent body. Specifically, the drug of the anticoagulant coating includes any one or more of aspirin, dipyridamole, clopidogrel, warfarin and heparin drugs. The drug loading is 0.1 mg / cm 2 ~3mg / cm 2 The drug in the anticoagulant coating is coated on the surface of the stent body by covalent grafting.

[0084] Specifically, the step of forming an anticoagulant coating on the surface of the stent body includes:

[0085] Performing surface treatment on the scaffold body to introduce reactive groups on the surface of the scaffold body;

[0086] A solution containing anticoagulant drugs is applied to the surface of the treated stent body, so that the reactive groups contained in the stent body react with the anticoagulant drugs to form an anticoagulant coating on the surface of the stent body.

[0087] In one embodiment, the drug of the anticoagulant coating is heparin, and the drug loading is 0.1 mg / cm 2 ~3mg / cm 2 , the preparation steps of the anticoagulant coating are as follows:

[0088] 1) The stent body is ultrasonically cleaned with ethanol, acetone and purified water for 10 minutes in sequence, and then dried for later use.

[0089] 2) Prepare an ethanol solution of 2% (v / v) octadecyl dimethyl benzyl ammonium chloride. Place the stent body in the solution, gently shake it at 37°C for 10 hours, wash the stent body with the same solvent and keep it in an oven at 70°C for 24 hours to enhance the binding of octadecyl dimethyl benzyl ammonium chloride to the stent body.

[0090] 3) The aminated stent body was immersed in an aqueous solution of heparin at a concentration of 2 mg / mL for 1 hour, and then rinsed with PBS. Finally, the stent body was dried at room temperature for 48 hours.

[0091] In some embodiments, before the step of forming an anti-coagulation coating on the surface of the stent body, the step further includes: performing a nitriding treatment or a fluoriding treatment on the stent body.

[0092] Specifically, the support body is nitrided by plasma to form a protective film. Specifically, the steps of nitridation treatment include: -3 Pa~3×10 -3 Pa, and the temperature of the bracket body is less than 50°C, nitrogen is introduced into the chamber at a pressure of 0.2Pa to 3.5Pa, glow discharge plasma is formed at 5MHz to 20MHz, and then a pulse bias voltage of -1kV to -10kV is applied for 3h to 7h to form a protective film with a thickness of 1μm to 12μm.

[0093] Specifically, the fluorination treatment step includes: placing the stent body into a hydrofluoric acid aqueous solution with a mass percentage concentration of 40% to 50%, stirring and soaking for 12 hours to 96 hours, and forming a protective film with a thickness of 100 μm to 300 μm on the surface of the stent body.

[0094] Nitriding or fluoriding the surface of the stent body can reduce the degradation rate of degradable pure iron or degradable iron-based alloy, avoiding the risk of rapid loss of mechanical strength in the early stage after implantation due to excessively fast degradation.

[0095] The preparation method of the glaucoma drainage stent is simple in process and easy to mass produce.

[0096] The third aspect of the present invention provides a method for treating glaucoma, comprising the following steps:

[0097] The glaucoma drainage stent is implanted into Schlemm's canal, so that the first end of the glaucoma drainage stent is connected to the anterior chamber, and the middle support part and the second end remain in Schlemm's canal. The glaucoma drainage stent is the glaucoma drainage stent of the above embodiment.

[0098] The above-mentioned treatment method for glaucoma is consistent with the characteristics of minimally invasive glaucoma surgery. After implantation, due to the pressure difference from the anterior chamber, the aqueous humor flows along the stent structure into the Schlemm's canal and into the aqueous humor circulation system, thereby reducing the patient's intraocular pressure and relieving glaucoma symptoms.

[0099] In order to make the purpose and advantages of the present invention clearer, the glaucoma drainage stent of the present invention and its effects are further described in detail in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and shall not be used to limit the present invention. The following embodiments do not include other components except inevitable impurities unless otherwise specified. The drugs and instruments used in the embodiments are conventionally selected in the art unless otherwise specified. The experimental methods for which specific conditions are not specified in the embodiments are implemented according to conventional conditions, such as the conditions described in the literature and books or the methods recommended by the manufacturer.

[0100] Example 1

[0101] This embodiment provides a glaucoma drainage stent, comprising a stent body, an iron fluoride protective film formed on the surface of the stent body, and an anticoagulant coating. Figure 1 The material of the stent body is pure iron with a purity of 99.95%, and the thickness of the protective film is 200μm. The anticoagulant drug used in the anticoagulant coating is heparin with a drug loading of 0.5mg / cm 2 .

[0102] The preparation process of the glaucoma drainage stent of this embodiment is as follows:

[0103] (1) Pure iron powder (purity 99.95%) with a particle size of less than 50 μm was integrally formed at 1140° C. by a powder metallurgy method to prepare a stent body.

[0104] (2) The formed stent body is immersed in a hydrofluoric acid aqueous solution with a mass percentage concentration of 48% for 24 hours to form a protective film with a thickness of 200 μm on its surface, thereby further enhancing the corrosion resistance of the stent body.

[0105] (3) An anticoagulant coating is formed on the surface of the stent body. The preparation steps are as described above, and the drug loading is 0.5 mg / cm 2 .

[0106] Example 2

[0107] This embodiment provides a glaucoma drainage stent, including a stent body and an anticoagulant coating formed on the surface of the stent body. Figure 1 The material of the stent body is Fe-Cu binary alloy, and the chemical composition of Fe-Cu binary alloy is as follows: Cu: 5%, and the rest is iron. The anticoagulant drug used in the anticoagulant coating is heparin, and the drug loading is 1 mg / cm 2 .

[0108] The preparation process of the glaucoma drainage stent of this embodiment is as follows:

[0109] (1) Weigh iron and copper raw materials by mass percentage, where the mass percentage of copper is 5% and the rest is iron. The iron and copper raw materials are repeatedly smelted to form an alloy solution, and Fe-Cu spherical powder with a particle size of <50μm is obtained by gas atomization process. Selective laser melting is used for integrated molding. The process parameters of sample printing are as follows: scanning interval 60μm, layer thickness 420μm, laser power 3400W and scanning speed 600mm / s to prepare the bracket body.

[0110] (2) An anticoagulant coating is formed on the surface of the stent body. The preparation steps are as described above, and the drug loading is 1 mg / cm 2 .

[0111] Example 3

[0112] This embodiment provides a glaucoma drainage stent, including a stent body and an anticoagulant coating formed on the surface of the stent body. Figure 1 The interior of the bracket body is also provided with Figure 2 The valve plate shown in the figure is made of a Fe-Pt binary alloy. The chemical composition of the Fe-Pt binary alloy is as follows: Pt: 5%, and the rest is iron. The anticoagulant drug used in the anticoagulant coating is heparin, and the drug loading is 0.5 mg / cm 2 .

[0113] The preparation process of the glaucoma drainage stent of this embodiment is as follows:

[0114] (1) According to the mass percentage, iron and platinum raw materials are weighed, wherein the mass percentage of platinum is 5% and the rest is iron. The raw materials are machined into a bracket body with an outer diameter of 0.7 mm to 1 mm and an inner diameter of 0.7 mm to 0.8 mm. The valve plate position is welded by argon arc welding, the welding current is 120A, and the argon gas flow rate is 5 L / min.

[0115] (2) An anticoagulant coating is formed on the surface of the stent body. The preparation steps are as described above, and the drug loading is 0.5 mg / cm 2 .

[0116] Example 4

[0117] This embodiment provides a glaucoma drainage stent, which is different from the embodiment 1 in that it does not contain a protective film.

[0118] Example 5

[0119] This embodiment provides a glaucoma drainage stent, which is different from the embodiment 3 in that the interior of the stent body does not contain a valve sheet.

[0120] Example 6

[0121] This embodiment provides a glaucoma drainage stent, which is different from the embodiment 1 in that it does not contain an anticoagulant coating.

[0122] Comparative Example 1

[0123] Comparative Example 1 provides a glaucoma drainage stent, which is different from Example 1 in that the material of the stent body is a zinc alloy, and the chemical composition of the zinc alloy used is Mg: 1.5% by mass, and the rest is zinc.

[0124] The performance of the above-mentioned glaucoma drainage stent was tested as follows:

[0125] 1. In vitro corrosion rate test: The corrosion resistance of glaucoma drainage stents was tested using an electrochemical workstation. The experimental temperature was 37°C, Hank's solution was selected as the electrolyte solution, the electrolytic cell was a standard three-electrode system, the stent sample was the working electrode, the platinum electrode was set as the auxiliary electrode, and the saturated KCl calomel electrode was used as the reference electrode. Before the test, a 1h open circuit potential test was performed to stabilize the electrode potential. Three parallel samples were prepared for each group of samples, and each sample was tested three times to obtain the corrosion potential V corr , corrosion current density I corr and corrosion rate v corr is the average value of all samples.

[0126] The specific corrosion rate test results are shown in Table 1. It can be seen from Table 1 that the corrosion rate of the glaucoma drainage stent of Example 1 is the slowest, and the corrosion rate of the glaucoma drainage stent of Comparative Example 1 is the highest. Compared with zinc alloy, pure iron and iron-based alloys show a slower degradation rate. Compared with iron-based degradable alloys, the pure iron of Example 1 with a protective layer has a longer degradation period, and compared with the pure iron stent without a protective layer, the degradation rate of Example 1 is slower, reflecting the slowing effect of the fluoride coating on the degradation rate.

[0127] Table 1 Experimental data on corrosion rate of glaucoma drainage stents in various embodiments and comparative examples

[0128]

[0129] 2. Mechanical stability test: The stent sample was immersed in Hank's solution and then subjected to a three-point bending test. The initial bending fracture load of the stent was recorded as N o The bending fracture load after immersion for 10 days, 30 days, 60 days, 90 days and 120 days is marked as N i , i is the corresponding immersion time (days), N i / N o The ratio of is used as a parameter to measure the bending load resistance of samples at different degradation time points, and the corresponding relationship between stent degradation and mechanical properties is studied.

[0130] Specific mechanical stability test results are as follows: Figure 3 As shown, the bending fracture load of the glaucoma drainage stent of Example 1 and Comparative Example 1 both showed a downward trend with the extension of the immersion time. In the early stage of immersion, the rate of decline was more obvious, and the downward trend continued to slow down in the later stage of immersion. The overall trend of Example 1 was consistent with that of Comparative Example 1, but the bending fracture load retention rate of Example 1 remained above 95%, showing a relatively excellent mechanical stability compared with Comparative Example 1.

[0131] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0132] The above-described embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solutions of the present invention in detail, but cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided by the present invention are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the contents of the attached claims, and the description and drawings can be used to interpret the contents of the claims.

Claims

1. A glaucoma drainage stent, characterized in that: The invention comprises a tubular stent body, wherein the stent body comprises a first end, an intermediate support portion and a second end connected in sequence, and the material of the stent body comprises a first degradable pure iron or a first degradable iron-based alloy.

2. The glaucoma drainage stent according to claim 1, characterized in that: A plurality of valve sheets with holes are arranged inside the support body, and the plurality of valve sheets are arranged at intervals along the extension direction of the tube. The material of the valve sheets includes second degradable pure iron or second degradable iron-based alloy.

3. The glaucoma drainage stent according to claim 2, characterized in that: The first degradable iron-based alloy and the second degradable iron-based alloy comprise iron-platinum alloy, and the mass percentage of platinum in the first degradable iron-based alloy and the second degradable iron-based alloy is independently 1% to 5%; or, The first degradable iron-based alloy and the second degradable iron-based alloy include an iron-copper alloy or an iron-silver alloy. In the first degradable iron-based alloy and the second degradable iron-based alloy, the mass percentage of copper or silver is independently 1% to 15%.

4. The glaucoma drainage stent according to claim 1, characterized in that: The support body meets at least one of the following conditions: 1) The glaucoma drainage stent can be implanted in Schlemm's canal to drain the aqueous humor of the anterior chamber; 2) The first end and / or the second end is a tapered structure; 3) The outer diameter of the intermediate support portion is larger than the inner diameter of Schlemm's canal.

5. The glaucoma drainage stent according to claims 1 to 4, characterized in that: Also includes: An anti-coagulation coating is arranged on the surface of the stent body.

6. The glaucoma drainage stent according to claim 5, characterized in that: The anticoagulant coating satisfies any one or more of the following conditions: 1) The drug loading of the anticoagulant coating is 0.1 mg / cm 2 ~3mg / cm 2 ; 2) The drug of the anticoagulant coating includes any one or more of aspirin, dipyridamole, clopidogrel, warfarin and heparin drugs; 3) The anticoagulant coating is connected to the stent body by covalent bonds.

7. The glaucoma drainage stent according to claim 5, characterized in that: A protective film is also provided on the surface of the stent body between the stent body and the anticoagulant coating; Optionally, the material of the protective film includes iron nitride or iron fluoride.

8. The glaucoma drainage stent according to claim 7, characterized in that: The material of the protective film includes iron nitride, and the thickness of the protective film is 1 μm to 12 μm; or, The material of the protective film includes iron fluoride, and the thickness of the protective film is 100 μm to 300 μm.

9. A method for preparing a glaucoma drainage stent, characterized in that: The steps include: A tubular stent body is prepared using a first degradable pure iron or a first degradable iron-based alloy as a material. The stent body comprises a first end, a middle support portion and a second end which are connected in sequence, thereby obtaining a glaucoma drainage stent.

10. The method for preparing the glaucoma drainage stent according to claim 9, characterized in that: The processing method of the stent body includes at least one of tube laser cutting, machining, additive manufacturing and powder metallurgy forming process; and / or, It also includes: forming a plurality of valve sheets with holes inside the bracket body, the plurality of valve sheets are arranged at intervals along the extension direction of the tube, and the material of the valve sheets includes a second degradable pure iron or a second degradable iron-based alloy.

11. The method for preparing a glaucoma drainage stent according to any one of claims 9 to 10, characterized in that: Also includes: An anti-coagulation coating is formed on the surface of the stent body.

12. The method for preparing the glaucoma drainage stent according to claim 11, characterized in that: The step of forming an anticoagulant coating on the surface of the stent body comprises: Performing surface treatment on the stent body to introduce reactive groups on the surface of the stent body; A solution containing anticoagulant drugs is applied to the treated surface of the stent body, so that the reactive groups contained in the stent body react with the anticoagulant drugs to form the anticoagulant coating on the surface of the stent body.

13. The method for preparing the glaucoma drainage stent according to claim 11, characterized in that: Before the step of forming the anticoagulant coating on the surface of the stent body, the method further includes: performing a nitriding treatment or a fluoriding treatment on the stent body.

14. The method for preparing the glaucoma drainage stent according to claim 13, characterized in that: The nitriding treatment step comprises: -3 Pa~3×10 -3 Pa, and the temperature of the bracket body is less than 50° C., nitrogen is introduced into the chamber at a pressure of 0.2Pa to 3.5Pa, glow discharge plasma is formed at 5MHz to 20MHz, and then a pulse bias voltage of -1kV to -10kV is applied for 3h to 7h to form a protective film with a thickness of 1μm to 12μm; The fluorination treatment step includes: soaking the stent body in a hydrofluoric acid aqueous solution with a mass percentage concentration of 40% to 50% for 12 hours to 96 hours, forming a protective film with a thickness of 100 μm to 300 μm on the surface of the stent body.